Le Lézard
Classified in: Health

PA5051 Shows 3-Fold Decrease In Body Fat And 5-Fold Increase In IL-6 Confirming Its Support For Weight Management

FAIRFIELD, N.J., July 17, 2019 /PRNewswire-PRWeb/ -- A new pilot study recently published in CDN (Current Developments In Nutrition) concluded that Pediococcus acidilactici NRRL B-50517 (PA-5051) is a safe probiotic for human consumption and may be useful in reducing body fat and pro-inflammatory markers. The study is entitled "Pediococcus Acidilactici NRRL B-50517 as a Safe Probiotic for Regulation of Weight-Related Pro-inflammatory Cytokines: A Double-blind Placebo-controlled Pilot Study (P21-026-19)."

Prepared by Dr. Jhy Jhu Lin, Imagilin Technology, LLC; Dr. Jeanne O'Connell, Restorasis Health at Sylvana Institute; and Dr. Steve Sinclair, Healing Power of Nature, the study was conducted over a three-month period. The goal was to determine the effectiveness of the probiotic PA-5051 in resisting high temperatures (up to 85°C), stomach acids and the air. Clinical evaluation of the effectiveness of PA-5051 as a safe probiotic for the regulation of weight-related health issues was also observed. 30 healthy participants were randomly assigned two capsules of placebo or PA-5051 (4 billion CFU) to be taken daily for three months. In order to ensure proper daily dosage administration and to collect the results of a questionnaire relating to 6 categories of gut functions for safety evaluation, bi-weekly phone interviews were conducted. Both percent of body fat and serum preparation for cytokine analysis were performed at the beginning and the end of clinic study.

No statistical differences between the control group and PA-5051 treated group was observed from all 6 categories of gut functions- appetite, energy, bowel movement, stool quality, bloating and gas through the three months study. This demonstrates that PA-5051 is a safe probiotic for human consumption. Interestingly, after taken three months with PA-5051 probiotics, the PA-5051 treated group showed a 3 fold decrease in the percent of body fat, 5 fold decrease in cytokine IL-6 and 2.6 fold decrease in cytokine IL-23 comparing those of control group. This indicates that PA-5051 may be applied for body weight management.

Link to review: https://dx.doi.org/10.1093%2Fcdn%2Fnzz041.P21-026-19


SOURCE A&B Ingredients

These press releases may also interest you

at 19:30
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for...

at 19:10
Alsana, an integrative and data-driven eating recovery program, will open a new location in Huntsville, Ala. in early 2020. Alsana will offer an eating disorder treatment program for adults 18+ with a Partial Hospitalization Program (PHP) and an...

at 19:05
STRICTLY FOR EUROPEAN MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY As the European distributor of Invokana® (canagliflozin) and Vokanamet® (canagliflozin and metformin), Mundipharma welcomes the news that the European Medicines Agency (EMA) has...

at 19:00
Bio-Rad Laboratories, Inc. , a global leader of life science research and clinical diagnostic products, announced that Fitch Ratings has upgraded Bio-Rad Laboratories, Inc.'s Long-Term Issuer-Default (IDR) to "BBB" from "BBB-." The upgrade reflects...

at 19:00
Dr. Parsa Mohebi, the founder of Parsa Mohebi Hair Restoration with locations in Los Angeles and Beverly Hills, recently opened his newest medical office in the city of San Francisco. The new office, staffed by Dr. Mohebi and his medical technicians,...

at 18:45
The latest edition of Crystallography Times from Rigaku Corporation has been published and is now available on the company's global website. Crystallography Times is a monthly electronic newsletter published by Rigaku focusing on single crystal X-ray...

News published on 17 july 2019 at 14:00 and distributed by: